

Amendments to the Claims:

Claim 1 (Previously Presented): An isolated glycoprotein comprising the human amino acid primary structure of CD55 and a tumor-specific N-linked glycostructure, wherein said glycoprotein has an apparent molecular weight of about 82 kD and is a glycoprotein present on adenocarcinoma cell line 23132 (DSMZ Accession No. DSM ACC 201), but not on a normal cell.

Claims 2-3 (Canceled).

Claim 4 (Previously Presented): A process for obtaining a glycoprotein according to claim 1, comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by size-exclusion chromatography.

Claims 5-41 (Canceled).

Claim 42 (Previously Presented): A process for obtaining a glycoprotein according to claim 1, comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by anion-exchange chromatography.

Claim 43 (Previously Presented): The isolated glycoprotein of claim 1, wherein said glycoprotein, if present on a cell and bound by an antibody that is specific for said glycostructure, results in apoptosis of said cell.

Claim 44 (Canceled).

Claim 45 (Previously Presented): The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in cleavage of cytokeratin 18 in said cell.

Claim 46 (Previously Presented): The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in increased c-myc expression in said cell.

Claim 47 (Previously Presented): The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in decreased topoisomerase II $\alpha$  expression in said cell.

Claim 48 (Previously Presented): The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in an increase in intracellular Ca<sup>2+</sup> concentration in said cell.

Claim 49 (Previously Presented): The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure does not induce cleavage of poly(ADP-ribose)-polymerase in said cell.

Claim 50 (Previously Presented): An isolated glycoprotein comprising a section of a glycosylated human CD55 protein expressed by adenocarcinoma cell line 23132 (DSMZ Accession No. DSM ACC 201), but not by a normal cell, wherein said glycosylated human CD55 protein has an apparent molecular weight of about 82 kD and wherein said section of said glycosylated human CD55 protein comprises a tumor-specific N-linked glycostructure.

Claim 51 (Currently Amended): The isolated glycoprotein of claim 50, wherein ~~said isolated glycoprotein, if present on a cell and bound by an antibody that is specific for said glycostructure, results in apoptosis of said cell~~ an antibody that specifically binds said tumor-specific N-linked glycostructure of said section, upon binding, induces apoptosis of a cell expressing said glycosylated human CD55 protein.

Claim 52 (Previously Presented): The isolated glycoprotein of claim 51, wherein binding of said antibody to said glycostructure results in cleavage of cytokeratin 18 in said cell.

Claim 53 (Previously Presented): The isolated glycoprotein of claim 51, wherein binding of said antibody to said glycostructure results in increased c-myc expression in said cell.

Claim 54 (Previously Presented): The isolated glycoprotein of claim 51, wherein binding of said antibody to said glycostructure results in decreased topoisomerase II $\alpha$  expression in said cell.

Claim 55 (Previously Presented): The isolated glycoprotein of claim 51, wherein binding of said antibody to said glycostructure results in an increase in intracellular Ca<sup>2+</sup> concentration in said cell.

Claim 56 (Previously Presented): The isolated glycoprotein of claim 51, wherein binding of said antibody to said glycostructure does not induce cleavage of poly(ADP-ribose)-polymerase in said cell.